- Stocks
- Healthcare
- NASDAQ: FATE

Price (delayed)

$89.75

Market cap

$8.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.12

Enterprise value

$8.43B

The company's equity has surged by 106% QoQ

FATE's revenue is up by 27% since the previous quarter

The company's quick ratio rose by 46% QoQ but it fell by 2.1% YoY

The net income has plunged by 65% YoY and by 7% from the previous quarter

The debt rose by 46% year-on-year and by 14% since the previous quarter

What are the main financial stats of FATE

Market
Valuations
Earnings

Shares outstanding

94.04M

Market cap

$8.44B

Enterprise value

$8.43B

Price to earnings (P/E)

N/A

Price to book (P/B)

10.65

Price to sales (P/S)

209.32

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

210.4

Revenue

$40.06M

EBIT

-$184.96M

EBITDA

-$181.62M

Free cash flow

-$47.5M

Per share
Balance sheet
Liquidity

EPS

-$2.12

Free cash flow per share

-$0.51

Book value per share

$8.42

Revenue per share

$0.43

TBVPS

$11.19

Total assets

$1.05B

Total liabilities

$255.87M

Debt

$110.92M

Equity

$790.1M

Working capital

$709.74M

Debt to equity

0.14

Current ratio

8.5

Quick ratio

8.59

Net debt/EBITDA

0.06

Margins
Efficiency
Dividend

EBITDA margin

-453.3%

Gross margin

100%

Net margin

-461.7%

Operating margin

-349%

Return on assets

-25.1%

Return on equity

-35.7%

Return on invested capital

-38.4%

Return on capital employed

-19.4%

Return on sales

-461.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Fate Therapeutics stock price performed over time

Intraday

1.5%

1 week

23.3%

1 month

15.06%

1 year

200.67%

YTD

-1.3%

QTD

8.85%

How have Fate Therapeutics's revenue and profit performed over time

Revenue

$40.06M

Gross profit

$40.06M

Operating income

-$139.8M

Net income

-$184.96M

Gross margin

100%

Net margin

-461.7%

The operating margin has soared by 68% YoY and by 14% from the previous quarter

The net income has plunged by 65% YoY and by 7% from the previous quarter

The net margin has surged by 56% year-on-year and by 16% since the previous quarter

FATE's revenue is up by 27% since the previous quarter

What is Fate Therapeutics's growth rate over time

What is Fate Therapeutics stock price valuation

P/E

N/A

P/B

10.65

P/S

209.32

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

210.4

FATE's EPS is down by 34% year-on-year

The company's equity has surged by 106% QoQ

FATE's price to book (P/B) is 66% higher than its 5-year quarterly average of 6.4 but 4.1% lower than its last 4 quarters average of 11.1

The stock's price to sales (P/S) is 72% more than its 5-year quarterly average of 121.7

FATE's revenue is up by 27% since the previous quarter

How efficient is Fate Therapeutics business performance

FATE's return on sales has surged by 56% year-on-year and by 16% since the previous quarter

The ROIC has grown by 39% YoY and by 30% from the previous quarter

Fate Therapeutics's return on assets has increased by 35% YoY and by 20% QoQ

The ROE has grown by 31% YoY and by 23% from the previous quarter

What is FATE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for FATE.

How did Fate Therapeutics financials performed over time

The total liabilities has soared by 149% YoY and by 8% from the previous quarter

FATE's total assets has surged by 68% since the previous quarter

The debt is 86% smaller than the equity

The company's equity has surged by 106% QoQ

The company's debt to equity has shrunk by 60% YoY and by 44% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.